Entrada Therapeutics, Inc. (TRDA): Total Assets
$377.38M
As of 2025-12-31
$298.88M
As of 2026-06-30
+14.4%
3-year compound annual growth
+54.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $377.38M | -28.3% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $526.32M | +12.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $469.19M | +86.1% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $252.06M | -17.6% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $305.83M | +602.6% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $43.53M | n/a | 2022-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| Celularity Inc (CELU) | 2025-12-31 | $107.33M | -19.1% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $42.21M | +31.1% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $198.10M | -30.2% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $246.44M | +142.7% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $25.65M | -52.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $59.03M | -34.9% |
Compare TRDA, CELU, ALMS, CUE side by side · Screen every company in Pharmaceutical Preparations ↗